Genetoo, the innovative biotech startup company, has made a breakthrough discovery in bacterial resistance. They have developed their first prototype surface that is resistant to bacterial formation and growth without the use of antibiotics. This surface is engineered with a specific type of laser treatment that leaves the surface very inhospitable for bacterial colonization. This means less likelihood of harmful, bacterial, infections.
Independent, laboratory tests yielded encouraging results certified with ISO 22196 standards. The technology was observed to inhibit the growth of Escherichia Coli by 94% and Staphylococcus Aureus by 78% compared to untread controls.
These two bacterial strains are responsible for the great majority of prosthetics infections. This Is of special interest to Genetoo, as they are working to create better prosthesis resistant to bacterial colonization hence to infections without the use of antibiotics.
Antibiotics resistance is the main burden of the medical industry. This “antibiotic free” treatment is a breakthrough in an era where antibiotic resistance became a global public health problem. Bacteria that develop resistance can be very difficult to eradicate and can cause further illness, and even death.
Genetoo is a company that has invested much time into bacterial resistant prosthetic implants. After incorporating in 2016, the Company has licensed a NASA patent and reverse engineered the protected technology, in order to make surfaces impervious to bacterial colonization.
These promising results made Genetoo’s investors even more optimistic about the company’s future. Genetoo intends to collaborate with other companies to make their technology available for patients as soon as possible.
Contact us to learn about our technology, investment opportunities, and our vision of a future free of bacterial infections without the use of antibiotics.
